CIDeRplusGeneral Information:
| Id: | 1,115 |
| Diseases: |
Parkinson disease
|
| Rattus norvegicus | |
| 6-OHDA-induced PD rat model | |
| BTO:0000143 substantia nigra | |
| article | |
| Reference: | Hu LF et al.(2010) Neuroprotective effects of hydrogen sulfide on Parkinsons disease rat models. Aging Cell 9: 135-146 [PMID: 20041858] |
Interaction Information:
| Comment | The endogenous H(2)S level was markedly reduced in the SN in a 6-hydroxydopamine (6-OHDA)-induced PD rat model. |
|
Formal Description Interaction-ID: 7159 |
drug/chemical compound 6-OHDA decreases_quantity of drug/chemical compound |
| Comment | Systemic administration of NaHS (an H(2)S donor) dramatically reversed the progression of movement dysfunction, loss of tyrosine-hydroxylase positive neurons in the SN. |
|
Formal Description Interaction-ID: 7160 |
|
| Comment | Systemic administration of NaHS (an H(2)S donor) dramatically reversed the progression of movement dysfunction, loss of tyrosine-hydroxylase positive neurons in the SN. |
|
Formal Description Interaction-ID: 7161 |
|
| Comment | Systemic administration of NaHS (an H(2)S donor) dramatically reversed the progression of movement dysfunction, loss of tyrosine-hydroxylase positive neurons in the SN. |
|
Formal Description Interaction-ID: 7162 |
|
| Comment | Administration of NaHS prevented the development of PD induced by rotenone. |
|
Formal Description Interaction-ID: 7163 |
|
| Comment | Administration of NaHS prevented the development of PD induced by rotenone. |
|
Formal Description Interaction-ID: 7164 |
|
| Comment | Administration of NaHS prevented the development of PD induced by rotenone. |
|
Formal Description Interaction-ID: 7165 |
drug/chemical compound NaHS decreases_activity of disease Parkinson disease |
| Comment | NaHS treatment inhibited microglial activation in the SN and accumulation of pro-inflammatory factors (e.g. TNF-alpha and nitric oxide) in the striatum via NF-kappaB pathway. |
|
Formal Description Interaction-ID: 7166 |
drug/chemical compound NaHS decreases_activity of process |
| Comment | NaHS treatment inhibited microglial activation in the SN and accumulation of pro-inflammatory factors (e.g. TNF-alpha and nitric oxide) in the striatum via NF-kappaB pathway. |
|
Formal Description Interaction-ID: 7167 |
drug/chemical compound NaHS decreases_quantity of gene/protein |
| Drugbank entries | Show/Hide entries for TNF |
| Comment | NaHS treatment inhibited microglial activation in the SN and accumulation of pro-inflammatory factors (e.g. TNF-alpha and nitric oxide) in the striatum via NF-kappaB pathway. |
|
Formal Description Interaction-ID: 7168 |
drug/chemical compound NaHS decreases_quantity of drug/chemical compound |
| Comment | H(2)S may serve as a neuroprotectant to treat and prevent neurotoxin-induced neurodegeneration. |
|
Formal Description Interaction-ID: 7169 |
|